JLL stock · XENE stock

JLL vs XENE · P/E 23, rev $13.31B vs $2.55B cap

Jones Lang LaSalle Incorporated (JLL) versus Xenon Pharmaceuticals Inc (XENE) — a side-by-side from cached financials, not a winner call.

Jones Lang LaSalle Incorporated (JLL) is a real estate services company listed on US.

Xenon Pharmaceuticals Inc (XENE) is a biotechnology company listed on US.

Latest reported JLL revenue for 2026-06-30 was $13.31B. Net income was $373.7M. JLL currently screens at market cap $12.12B and trailing P/E 23.0.

Latest reported XENE revenue for 2026-06-30 was $0. Net income was -$213.0M. XENE currently screens at market cap $2.55B.

JLL currently screens at market cap $12.12B and trailing P/E 23.0. XENE currently screens at market cap $2.55B.

Not investment advice. Open the JLL and XENE stock pages for the full models.

Not investment advice.

Popular Stock Comparisons